The DOI matches its Crossref record; 249 of the 249 references it cites were found in a registry or an index.
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and recommended approaches to genetic testing/counseling and management strategies in individuals with these pathogenic or likely pathogenic variants. This manuscript focuses on cancer risk and risk management for BRCA-related breast/ovarian cancer syndrome and Li-Fraumeni syndrome. Carriers of a BRCA1/2 pathogenic or likely pathogenic variant have an excessive risk for both breast and ovarian cancer that warrants consideration of more intensive screening and preventive strategies. There is also evidence that risks of prostate cancer and pancreatic cancer are elevated in these carriers. Li-Fraumeni syndrome is a highly penetrant cancer syndrome associated with a high lifetime risk for cancer, including soft tissue sarcomas, osteosarcomas, premenopausal breast cancer, colon cancer, gastric cancer, adrenocortical carcinoma, and brain tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–249 of 249
A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer
Lang, S., Swift, S. L., White, H., Misso, K., Kleijnen, J., & Quek, R. G. W. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4842 · Cited by 103
Chen, J., Bae, E., Zhang, L., Hughes, K. S., Parmigiani, G., Braun, D., & Rebbeck, T. R. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa029 · Cited by 103
Marchetti, C., Felice, F. D., Boccia, S. M., Sassu, C. M., Donato, V. D., Perniola, G., Palaia, I., Monti, M., Muzii, L., Tombolini, V., et al. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.09.018 · Cited by 100
Krutilkova, V., Trková, M., Fleitz, J. M., Gregor, V., Novotna, K., Křepelová, A., Sumerauer, D., Kodet, R., Širůčková, S., Plevová, P., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.01.026 · Cited by 97
Lee, E., Ma, H., McKean‐Cowdin, R., Berg, D. V. D., Bernstein, L., Henderson, B. E., & Ursin, G. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0396 · Cited by 97
Mouchawar, J., Korch, C. T., Byers, T., Pitts, T. M., Li, E., McCredie, M. R. E., Giles, G. G., Hopper, J. L., & Southey, M. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-0851 · Cited by 92
Pediatric Cancer Predisposition Imaging: Focus on Whole-Body MRI
Greer, M. C., Voss, S. D., & States, L. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0515 · Cited by 92
Rechsteiner, M., Zimmermann, A., Wild, P. J., Caduff, R. F., von Teichman, A., Fink, D. A., Moch, H., & Noske, A. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.08.004 · Cited by 91
Routine TP53 testing for breast cancer under age 30: ready for prime time?
McCuaig, J. M., Armel, S. R., Novokmet, A., Ginsburg, O., Demsky, R., Narod, S. A., & Malkin, D. M. (2012) · Familial Cancer · doi:10.1007/s10689-012-9557-z · Cited by 89
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer
Evans, D. G., Howell, A., Ward, D., Lalloo, F. I., Jones, J. L., & Eccles, D. (2011) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100006 · Cited by 87
Jong, M. A.-D., de Bock, G. H., van Asperen, C. J., Mourits, M. J. E., de Hullu, J. A., & Kets, C. M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.009 · Cited by 87
Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women
Schmidt, M. K., van den Broek, A. J., Tollenaar, R. A. �. �., Smit, V. T. H. B. M., Westenend, P. J., Brinkhuis, M., Oosterhuis, W., Wesseling, J., Janssen-Heijnen, M. L. G., Jobsen, J. J., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw329 · Cited by 87
Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers
Lee, L. J., Alexander, B. M., Schnitt, S. J., Comander, A. H., Gallagher, B. M., Garber, J. E., & Tung, N. (2011) · Cancer · doi:10.1002/cncr.25911 · Cited by 86
Eerola, H., Heikkilä, P., Tamminen, A., Aittomäki, K., BLOMQVIST, C. P., & Nevanlinna, H. A. (2005) · Breast Cancer Research · doi:10.1186/bcr1025 · Cited by 80
Lucas, A. L., Shakya, R., Lipsyc, M. D., Mitchel, E. B., Kumar, S., Hwang, C., Deng, L., DeVoe, C., Chabot, J. A., Szabolcs, M. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3020 · Cited by 80
CDKN2A is the main susceptibility gene in Italian pancreatic cancer families
Ghiorzo, P., Fornarini, G., Sciallero, S., Battistuzzi, L., Belli, F., Bernard, L., Bonelli, L. A., Borgonovo, G., Bruno, W., Cian, F. D., et al. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100281 · Cited by 77
Bermejo, J. L., & Hemminki, K. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh474 · Cited by 77
Preimplantation Genetic Diagnosis for Cancer Syndromes
Offit, K., Sagi, M., & Hurley, K. E. (2006) · JAMA · doi:10.1001/jama.296.22.2727 · Cited by 76
Self-citationSalpingectomy as a Means to Reduce Ovarian Cancer Risk
Daly, M. B., Drescher, C. W., Yates, M. S., Jeter, J., Karlan, B. Y., Alberts, D. S., & Lu, K. H. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0293 · Cited by 75
Self-citationPreimplantation genetic diagnosis for BRCA1/2—a novel clinical experience
Sagi, M., Weinberg, N., Eilat, A., Aizenman, E., Werner, M., Girsh, E., Siminovsky, Y., Abeliovich, D., Peretz, T., Simon, A., et al. (2009) · Prenatal Diagnosis · doi:10.1002/pd.2232 · Cited by 74
Lippman, M. E., Cummings, S. R., Disch, D. P., Mershon, J. L., Dowsett, S. A., Cauley, J. A., & Martino, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0688 · Cited by 73
Ingle, J. N., Liu, M., Wickerham, D. L., Schaid, D. J., Wang, L., Mushiroda, T., Kubo, M., Costantino, J. P., Vogel, V. G., Paik, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0038 · Cited by 72
Skin cancer risk inBRCA1/2mutation carriers
Gumaste, P. V., Penn, L. A., Cymerman, R. M., Kirchhoff, T., Polsky, D., & McLellan, B. N. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13626 · Cited by 69
Effect of Mammography on Breast Cancer Risk in Women with Mutations in BRCA1 or BRCA2
Goldfrank, D. J., Chuai, S., Bernstein, J. L., y Cajal, T. R., Lee, J. B., Alonso, M. C., Díez, O., Baiget, M., Kauff, N. D., Offit, K., et al. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0176 · Cited by 67
Self-citationLee, D. S., Yoon, S., Looi, L., Kang, P. C. E., Kang, I. N., Sivanandan, K., Ariffin, H., Thong, M., Chin, K. F., Taib, N. A. M., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3172 · Cited by 67
Mai, P. L., Khincha, P. P., Loud, J. T., DeCastro, R. M., Bremer, R. C., Peters, J. A., Liu, C., Bluemke, D. A., Malayeri, A. A., & Savage, S. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1350 · Cited by 65
de Jonge, M. M., Mooyaart, A. L., Vreeswijk, M. P. G., de Kroon, C. D., van Wezel, T., van Asperen, C. J., Smit, V. T. H. B. M., Dekkers, O. M., & Bosse, T. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.11.028 · Cited by 64
Xiao, Y., Wang, K., Liu, Q., Li, J., Zhang, X., & Li, H. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.09.011 · Cited by 60
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study
Bjørge, T., Lie, A. K., Hovig, E. J., Gislefoss, R. E., Hansen, S., Jellum, E., Langseth, H., Nustad, K., Tropé, C. G., & Dørum, A. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602199 · Cited by 57
Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer
Rummel, S. K., Varner, E. L., Shriver, C. D., & Ellsworth, R. E. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2348-2 · Cited by 57
Oestrogen receptor status and survival in women with BRCA2-associated breast cancer
Metcalfe, K. A., Lynch, H. T., Foulkes, W. D., Tung, N., Olopade, O. I., Eisen, A. F., Lerner‐Ellis, J. P., Snyder, C., Kim, S. J., Sun, P., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0376-y · Cited by 51
Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk
Terry, M. B., Daly, M. B., Phillips, K. A., Ma, X., Zeinomar, N., Leoce, N., Dite, G. S., MacInnis, R. J., Chung, W. K., Knight, J. A., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy182 · Cited by 50
Self-citationMultiple Primary Cutaneous Melanomas in Li-Fraumeni Syndrome
Curiel‐Lewandrowski, C. N., Speetzen, L. S., Cranmer, L. D., et al. (2011) · Archives of Dermatology · doi:10.1001/archdermatol.2010.428 · Cited by 45
Jasper, M. J., Liebelt, J. E., & Hussey, N. D. (2008) · Prenatal Diagnosis · doi:10.1002/pd.1925 · Cited by 43
Jonasson, J. G., Stefánsson, Ó. A., Johannsson, O. T., Sigurdsson, H., Agnarsson, B. A., Ólafsdóttir, G. H., Alexiusdottir, K. K., Stefansdóttir, H., Mitev, R. M., Olafsdottir, K., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.249 · Cited by 43
The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30
Ginsburg, O., Akbari, M. R., Aziz, Z., Young, R., Lynch, H. T., Ghadirian, P., Robidoux, A., Hernández, J. E. L., Vásquez, G., Gomes, M. C. B., et al. (2009) · Familial Cancer · doi:10.1007/s10689-009-9287-z · Cited by 40
Keupp, K., Hampp, S., Hübbel, A., Maringa, M., Kostezka, S., Rhiem, K., Waha, A., Wappenschmidt, B., Pujol, R. M., Surrallés, J., et al. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.863 · Cited by 40
Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers
Laitman, Y., Michaelson‐Cohen, R., Levi, E., Chen‐Shtoyerman, R., Reish, O., Josefsberg, S. B. Y., Bernstein‐Molho, R., Keinan‐Boker, L., Rosengarten, O. S., SILVERMAN, B. G., et al. (2018) · Cancer · doi:10.1002/cncr.31842 · Cited by 39
Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers
Lee, Y. C., Milne, R. L., Lheureux, S., Friedlander, M. L., McLachlan, S., Martin, K. L., Bernardini, M. Q., Smith, C. L., Picken, S., Nesci, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.004 · Cited by 38
Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients.
Verhoog, L. C., Berns, E., Brekelmans, C. T. M., Seynaeve, C., Meijers-Heijboer, E. J., & Klijn, J. G. M. (2000) · PubMed · Cited by 35
The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li–Fraumeni-like kindreds
Siddiqui, R., Onel, K., Facio, F. M., Nafa, K., Díaz, L. R., Kauff, N. D., Huang, H. J., Robson, M. E., Ellis, N. A., & Offit, K. (2005) · Familial Cancer · doi:10.1007/s10689-004-1946-5 · Cited by 33
Self-citationIqbal, J., Nussenzweig, A., Lubiński, J., Byrski, T., Eisen, A. F., Bordeleau, L. J., Tung, N., Manoukian, S., Phelan, C. M., Sun, P., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.58 · Cited by 32
Rush, S. K., Swisher, E. M., Garcia, R. L., Pennington, K. P., Agnew, K. J., Kilgore, M., & Norquist, B. M. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.02.006 · Cited by 31
Self-citationStjepanovic, N., Villacampa, G. J., Nead, K. T., Torres‐Esquius, S., Melis, G. G., Nathanson, K. L., Teulé, À., Brunet, J., y Cajal, T. R., Llort, G., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.009 · Cited by 25
Self-citationDigital Breast Tomosynthesis Changes Management in Patients Seen at a Tertiary Care Breast Center
Margolies, L. R., Cohen, A., Sonnenblick, E. B., Mandeli, J., Schmidt, P. H., Szabo, J. R., Patel, N., Hermann, G., Weltz, C., & Port, E. R. (2014) · ISRN Radiology · doi:10.1155/2014/658929 · Cited by 24
A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma
Dong, F., Davineni, P. K., Howitt, B. E., & Beck, A. H. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0286 · Cited by 22
Prophylactic Oophorectomy and Hormone Replacement Therapy: Protection at What Price?
Garber, J. E., & Hartman, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.926 · Cited by 20
How Well Does Supplemental Screening Magnetic Resonance Imaging Work in High-Risk Women?
Berg, W. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2975 · Cited by 16
Cancer Screening in Li-Fraumeni Syndrome
Asdahl, P. H., Ojha, R. P., & Hasle, H. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2459 · Cited by 12
Cited by
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian
Mersch, J., Jackson, M. A., Park, M., Nebgen, D., Peterson, S. K., Singletary, C., Arun, B. K., & Litton, J. K. (2015) · Cancer · doi:10.1002/cncr.29041 · Cited by 511
Self-citationHereditary diffuse gastric cancer: updated clinical practice guidelines
Blair, V. R., McLeod, M., Carneiro, F., Coit, D. G., D'Addario, J. L., van Dieren, J. M., Harris, K. L., Hoogerbrugge, N., Oliveira, C., van der Post, R. S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30219-9 · Cited by 491
Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment
Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., Whittemore, A. S., McGuire, V., Ladabaum, U., Kobayashi, Y., Lincoln, S. E., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6607 · Cited by 485
Self-citationSessa, C., Balmaña, J., Bober, S. L., Cardoso, M. J., Colombo, N., Curigliano, G., Domchek, S. M., Evans, D. G., Fischerova, D., Harbeck, N., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.004 · Cited by 295
Self-citation
Metadata
- Authors
- Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., CGC, Karlan, B. Y., Khan, S., Klein, C., Kohlmann, W., CGC, Kurian, A. W., Laronga, C., Litton, J. K., Mak, J. S., LCGC, Menendez, C. S., Merajver, S. D., Norquist, B. S., Offit, K., Pederson, H. J., Reiser, G., CGC, Senter-Jamieson, L., CGC, Shannon, K. M., Shatsky, R., Visvanathan, K., Weitzel, J. N., Wick, M. J., Wisinski, K. B., Yurgelun, M. B., Darlow, S. D., & Dwyer, M. A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2021-01-06
- Volume
- 19
- Issue
- 1
- Pages
- 77-102
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W3118983547
- Cited by
- 1,112
- References
- 249
- FWCI
- 106.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.